Advertisement

Picture Berlin Partner HealthCapital Bionnale 2018 June Matchmaking 600x60px
Document › Details

Pierre Fabre S.A.. (12/14/15). "Press Release: Pierre Fabre and Cordeliers Research Centre Sign Strategic Partnership to Identify New Therapeutic Targets in Immuno-oncology". Castres.

Region Region France
Organisations Organisation Pierre Fabre, Center of Immunology (CIPF)
  Group Pierre Fabre (Group)
  Organisation 2 Cordeliers Research Center (CRC) (Inserm)
  Group France (govt)
Products Product cancer immunotherapy (immuno-oncology, I-O)
  Product 2 drug target identification
Persons Person Corvaïa, Nathalie (Pierre Fabre 201404 Managing Director of Center of Immunology Pierre Fabre)
  Person 2 Audoly, Laurent (Kymera Thearapeutics 201710– CEO before Pierre Fabre SVP RnD before Pieris 201006–2010307 CSO)
     


# Inserm’s Cordeliers Research Centre is internationally recognized for its expertise in immuno-oncology. Pierre Fabre has extensive experience in oncology, priority for its pharmaceutical R&D.

# Both partners will work closely together for the next 3 years to identify new biological targets and develop innovative therapies in immuno-oncology.

# The partnership is facilitated by Inserm Transfert, Inserm's subsidiary dedicated to knowledge transfer.


Pierre Fabre Médicament (PFM) announces a strategic partnership with Inserm and its academic partners (Université Paris Descartes-Paris V, Université Pierre et Marie Curie-Paris VI and Université Paris Diderot-Paris VII) and Inserm Transfert to identify new therapeutic targets in immuno-oncology. Under the terms of this 3-year agreement, Inserm’s Cordeliers Research Center (CRC) and the Center of Immunology Pierre Fabre (CIPF) will work closely to develop tomorrow’s oncological biotherapies. Through periodic collaborative workshops, the CRC teams of Pr. Wolf-Hervé Fridman and CIPF teams will discuss their research and share their expertise in immuno-oncology. This knowledge transfer will combine CRC’s academic scientific excellence and Pierre Fabre’s know-how in the development of biomolecules and in translational medicine, as a way to select patients who might benefit the most from these new targeted treatments.

At first, the CIPF scientists and CRC teams will validate the therapeutic value of the biological targets discovered by the academic researchers. Pierre Fabre teams will bring their expertise in the development of monoclonal antibodies corresponding to these targets. Meanwhile, both entities will work together to identify new therapeutic targets. Academic research will therefore immediately be translated into therapeutic advances adapted to the needs of patients. Meant to bridge the gap between academic and applied research, this partnership aims to provide patients with future immunotherapies against cancer.

Pierre Fabre has extensive experience in oncology and immunology. The CIPF, which focuses on the fight against cancer, specializes in researching targeted biotherapies. Located in Saint-Julien-en-Genevois, it aims at finding monoclonal antibodies used in oncology treatments and the production of biotechnological active substances. Since the creation in 2011 of its Antibodies Biotechnology Unit (ABU), the CIPF is the only French institution to combine applied research, developments and the production of clinical batches, all at the same site. With its translational medicine and clinical oncological expertise, Pierre Fabre is an ideal partner for the development of new therapies in immuno-oncology.

A pioneer of cancer immunology and immunotherapy, the CRC, currently headed by Pr. Pascal Ferré, is internationally recognized for its expertise in these fields. The Center was created in 2007 by Pr. Hervé Fridman, a specialist in clinical immunology, under the joint supervision of Inserm, Université Pierre et Marie Curie, Université Paris Descartes, and Université Paris Diderot-Paris. The research teams of the CRC Department “Cancer, Immunology and Immunopathology” focus on the study of the dialogue between the immune system and cancer, especially within the tumor microenvironment. They are looking into the stress signals induced by different treatments (chemotherapy, antibody therapies) and their impact on the anti-tumor response.

“Most of my research has been dedicated to fighting cancer and discovering the best approach to win this fight. By combining our respective expertises, this partnership with Pierre Fabre offers us a unique opportunity to promote the development of our latest discoveries, so that they can become innovative anti-cancer immunotherapies,” welcomed Dr. Wolf-Hervé Fridman.

"We are delighted to have concluded this agreement which is key in its duration and ambition. This partnership, at the heart of Inserm’s strategic priorities of innovation, has also been signed with a French partner who repeatedly showed in the past its ability to work closely with academic research teams”, says Pascale Augé, Chairman, Inserm Transfert.

“We are looking forward to implement this strategic partnership in immuno-oncology with such a renowned research center of Inserm. This collaboration will strengthen and increase our ability to develop new targeted biomolecules. This partnership is fully aligned with the Open Innovation strategy that Pierre Fabre Médicament wants to develop” added Nathalie Corvaia, Managing Director of the CIPF.

“Pierre Fabre Médicament is deeply committed to the development of new molecules and targeted therapies in oncology, a therapeutic priority for its R&D. This partnership with Inserm will strengthen our internal capabilities to meet not yet covered therapeutic needs in oncology,” commented Dr. Laurent Audoly, Head of Research and Development at Pierre Fabre Médicament.


About Pierre Fabre

Pierre Fabre is a French privately owned health and beauty care company created in 1961 by Mr. Pierre Fabre. In 2014, global sales reached €2.1 billion across 130 countries. The company is structured around two divisions: Pharmaceuticals (prescription drugs, consumer health care) and Dermo-cosmetics (including the European and Asian market-leader Eau Thermale Avène brand). Pierre Fabre employs 10,000 people worldwide and owns subsidiary in 43 countries. In 2014, the company allocated 17 percent of its pharmaceuticals sales to R&D with a focus on 4 therapeutic areas: oncology, dermatology, CNS and consumer health care.

Pierre Fabre’s oncology know-how is based on 3 decades of experience in the discovery, development and global commercialization of innovative cancer drugs including monoclonal antibodies and natural cytotoxic agents. The company performs its oncology R&D in two major research centers: the Center of Immunology Pierre Fabre (CIPF) based in Saint-Julien-en-Genevois (France) and the Pierre Fabre Research Institute (IRPF) located on the Toulouse-Oncopole campus. The latter is officially recognized as a National Center of Excellence for Cancer Research.

For more information on Pierre Fabre, please go to www.pierre-fabre.com


About the Center of Immunology Pierre Fabre (CIPF)

The CIPF is a center of excellence in the field of biotechnology and one of the rare sites in France to combine the research, development and production of biological entities. Thanks to its research activities, Pierre Fabre has become a leader in the identification and evaluation of biomolecules’ therapeutic potential. Widely recognized for its work, the CIPF focuses on research in cancer immunotherapy, including the identification of monoclonal antibodies for therapeutic purposes. With over 20 years of experience, its Industrial Development teams are dedicated to designing biomolecule manufacturing processes. The Antibodies Biotechnology Unit (ABU), created in 2011, uses those designs to manage the production of biomolecules in situ. Always looking to improve and share its expertise, the CIPF has created many partnerships over the years with key players in the fields of research and biotechnology. For more information, please go to www.cipf.com


About the Institut national de la santé et de la recherche médicale (Inserm)

Founded in 1964, the French National Institute of Health and Medical Research (Inserm) is a public scientific and technological institute, which operates under the joint authority of the French Ministry of Health and Ministry of Research. As the only French public research institute entirely dedicated to human health, Inserm took on the responsibility of the strategic, scientific and operational coordination of France’s biomedical research in 2008. To carry out its key role as coordinator, Inserm relies on the quality of its scientific teams and its ability to conduct translational research, from the lab to the patient’s bed. For more information, please go to www.inserm.fr


About Inserm Tansfert

Inserm Transfert is a subsidiary of Inserm dedicated to knowledge transfer and the promotion of biomedical discoveries made by the Institute’s teams. It identifies technologies and innovations with a strong market potential and implements the appropriate maturation, IP and manufacturing strategies as a way to foster the development of innovative health products. Inserm Transfert also provides engineering and research project management services, offering its partners the expertise, support and guidance required for the creation and management of strategic research partnerships, international research consortia and large-scale projects in public health. Primarily dedicated to servicing scientists, Inserm Transfert creates value at the heart of the innovation process, thus contributing to patients’ health, society’s progress and economic growth. For more information, please go to: www.inserm-transfert.fr

Sources: http://www.crc.jussieu.fr; http://www.cipf.com


Contacts:

Valérie Roucoules
Pierre Fabre
Deputy Director Media Relations
Tel.: +33 1 49 10 83 84
Email: valerie.roucoules@pierre-fabre.com

ALIZE RP
Caroline Carmagnol/Florence Portejoie
and Wendy Rigal
Tel.: + 33 1 44 54 36 66
Email: pierre-fabre@alizerp.com

   
Record changed: 2018-05-15

Advertisement

Picture EBD Group Biotech Showcase 2019 San Francisco BTS January 600x60px

More documents for Pierre Fabre (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group Bio-Europe 2018 Copenhagen Denmark November 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture Berlin Partner HealthCapital Bionnale 2018 Germany June 120x240px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Picture Berlin Partner HealthCapital Bionnale 2018 June Matchmaking 120x240px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group Biotech Showcase 2019 San Francisco BTS January 120x180px Picture EBD Group Bio-Europe 2018 Copenhagen Denmark November 120x180px